Abstract
Brain metastases are associated with significant morbidity and poor survival outcomes. They are found in 10-20% of patients with non-small cell lung cancer (NSCLC) at presentation, and in up to 50% of patients during the course of their illness. Brain metastases occur most frequently in patients with adenocarcinoma and tumor harbouring epidermal growth factor receptor (EGFR) mutations or ALK rearrangements, especially after treating with 1st or 2nd generation EGFR TKI. Aumolertinib, the third generation irreversible EGFR TKI, has been developed to target T790M mutation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
